S. Zencir Et Al. , "Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.146, no.7, pp.1671-1676, 2020
Zencir, S. Et Al. 2020. Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.146, no.7 , 1671-1676.
Zencir, S., Hsieh, M., Hsu, J., Ergun, Y., Chou, G., Li, T., ... Teng, S.(2020). Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.146, no.7, 1671-1676.
Zencir, Sevil Et Al. "Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.146, no.7, 1671-1676, 2020
Zencir, Sevil Et Al. "Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.146, no.7, pp.1671-1676, 2020
Zencir, S. Et Al. (2020) . "Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.146, no.7, pp.1671-1676.
@article{article, author={Sevil Zencir Et Al. }, title={Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2020, pages={1671-1676} }